Container Closure Integrity (CCI) is fundamental to pharmaceutical product safety, acting as the primary barrier that protects drug products from contamination and degradation. The right combination of vial, stopper, and seal also supports smooth fill‑and‑finish operations, which has become increasingly important as high‑value and small‑batch drugs become more common, and manufacturers aim to minimize product loss.

Achieving strong CCI and robust process performance depends on the careful integration of vial, stopper, and seal. This article examines how close alignment of container and closure systems enhances machinability, reduces avoidable losses, and strengthens CCI. It also highlights how collaboration between component manufacturers enables pre‑qualified combinations that deliver consistent and dependable results.

The anatomy of a vial

Vial neck designs play a crucial role in achieving optimum Container Closure Integrity (CCI), with the primary types being European Blowback (EBB), No Blowback (NBB), and the less requested and less recommended American Blowback (ABB).

EBB necks feature a slight internal bulge that helps secure the stopper during assembly before sealing. After crimping, the combination of vial, stopper and seal creates a tight closure. Widely used, EBB is the preferred choice for many pharmaceutical applications.

NBB necks eliminate the internal recess, providing a smooth internal surface that can promote consistent stopper seating and strong CCI. However, they may require more precise assembly and compatibility assessments between vial and stopper.

ABB necks are characterized by a more pronounced internal blowback that forms an indent in the neck’s internal surface. However, they are currently experiencing decreased interest in the market and are not recommended due to their complex production process and resulting variation in uniformity, which creates unnecessary potential for compromised CCI. Hence, this blowback type is not usually recommended by SCHOTT Pharma.

Selecting the appropriate neck type is essential, as it directly impacts the effectiveness of the container closure system and the overall safety of your pharmaceutical product. The EBB neck is a safe choice as it enables secure stopper placement and reduces the risk of pop-up or even pop-off between the stopper and crimping unit. It can provide a one-size-fits-all solution that’s highly beneficial for both liquid and lyo formulations as the bulge supports stopper placement.

Anatomy of a rubber stopper

The primary role of a rubber stopper is to close the container and, as a result, protect the sterility and stability of the drug product. Stopper design is a key factor in achieving this, as its geometry and material properties directly influence Container Closure Integrity (CCI) and fill‑and‑finish performance. A stopper can be described by two key areas: the flange and the plug.

The flange is the upper part of the stopper and includes a target area to support consistent needle or spike penetration. Optimized flange features, such as anti‑sticking marks, help reduce clumping in feeder bowls, while controlled flange thickness supports consistent machinability. The trim edge of the flange is a small ring of rubber created during the cutting step of stopper manufacturing. Although it does not contribute to sealing, it must be carefully controlled to avoid particle formation, machinability issues, or capping defects. The underside of the flange forms the land seal against the vial rim, a critical interface for long‑term CCI after crimping.

The plug is the lower part of the stopper that enters the vial neck and establishes the initial interference fit that provides temporary sealing before crimping. The correct diameter of the plug is essential: if too large, insertion may be difficult or induce pop‑up; if too small, voids can compromise the seal and result in leakage. The presence of a blowback feature in the plug offers an additional layer of security to guard against these risks.

It’s not just the geometry of the container and stopper that can have an impact on CCI. The formulation of the stopper compound and its surface coating can influence compatibility, ease of processing, and compliance with safety requirements. As with selecting the correct vial neck, choosing the right stopper design requires careful alignment with the container system and the intended manufacturing process.

Putting components into action – common struggles during the fill-and-finish process

During drug product filling, vials, stoppers, and seals are essential for both efficient fill-and-finish operation and ensuring patient safety. The compatibility between stopper and vial is especially critical for correct stopper placement and maintaining Container Closure Integrity (CCI) after crimping.

a) Efficient fill-and-finish operations with limited pop-up/pop-off

Selecting the right combination of vial and stopper plays a critical role in supporting robust fill-and-finish operations and preventing failures such as pop-up or pop-off. Pop-up refers to the phenomenon where the stopper rises slightly from its seated position at the point between insertion and crimping, potentially compromising CCI.

Pop-off is a more critical event where the stopper is completely ejected from the vial neck, leading to loss of product sterility and safety. These behaviors can result from factors such as low stopper insertion forces or vial overfill that increases internal pressure. However, strong compatibility between the vial neck’s design and stopper geometry significantly reduces their occurrence, especially during high-speed operations.

Testing conducted by SCHOTT Pharma and Datwyler to evaluate the impact of blowback compatibility found that blowback features reduce the risk of pop-up and pop-off events. Configurations using either a blowback stopper, blowback vial, or both, performed reliably, whereas the absence of blowback in both components increased the likelihood of container closure system failure.

b) Ensuring patient safety with robust CCI

Container Closure Integrity can only be achieved by using a solid combination of vial, stopper, and seal. When used together, all three components form two solid seals, which are ultimately responsible for maintaining drug sterility over the entire shelf life.

The plug seal refers to the seal formed at the interface between the stopper plug and the inner surface of the vial neck. This seal is tightest at the narrowest section of the vial neck and/or the widest section of the stopper plug. It represents the first closure step and is achieved during stopper placement. While it does not constitute a fully secure or permanent seal on its own, it is designed to provide the initial vial closure prior to crimping.

In contrast, the land seal is located between the vial’s top rim and the stopper’s land seal. It is formed during crimping, when the aluminum cap compresses the stopper and firmly secures it against the top rim of the vial. Unlike the plug seal, the land seal relies primarily on the compressive force applied by the aluminum cap during crimping to create a tight and durable container closure system.

SCHOTT Pharma and Datwyler conducted pharmaceutical Container Closure Integrity (CCI) tests on batches of 2R EBB and NBB vials after filling, stoppering, and crimping. The tests included all possible combinations of vial and stopper types: EBB and NBB vials paired with blowback (BB) and no-blowback (NB) stoppers. In every configuration, the measurements remained well below the required thresholds, confirming the robust performance of each combination and showing that the blowback feature had no adverse impact on CCI.

Partnering for success

The strong partnership between component manufacturers such as SCHOTT Pharma and Datwyler plays a crucial role in reinforcing the reliability of complete packaging solutions. By providing pre-tested solutions, these collaborations help to minimize the risk of fill-and-finish inefficiencies and support solid Container Closure Integrity (CCI), as demonstrated by the consistent test results.

Easy accessibility to a wide range of components through SCHOTT Pharma’s Fast Track Kit or Datwyler’s StarterPack, which include pre-sterilized, ready-to-use vials, stoppers, and seals in validated configurations, offers customers a convenient, one-stop-shop approach. In addition, Container Closure Integrity datasheets are readily available for selected vial and stopper combinations, giving manufacturers confidence in the sterility and performance of their packaging throughout the product lifecycle.

At a glance

• The blog explains that Container Closure Integrity (CCI) ensures sterile pharmaceutical products remain free from microbial ingress, contamination, and product loss throughout shelf life.
• Regulatory authorities including the FDA and USP require validated CCI testing as part of sterile drug product quality assurance and lifecycle management.
• Deterministic CCI testing methods such as helium leak detection, vacuum decay, and high-voltage leak detection provide higher sensitivity and reproducibility than probabilistic methods like dye ingress testing.
• Packaging components, filling processes, transportation stress, and storage conditions can all affect container closure integrity and must be evaluated during product development.
• SCHOTT Pharma highlights that integrated packaging solutions and early CCI assessment can reduce risk, support regulatory compliance, and improve drug product safety.